Notably, the transcriptional levels of ESR1 are significantly decreased in relapsed lesions compared with primary tissues in tamoxifen‐treated breast cancer (Johnston et al, 1995; Drury et al, 2011; Kim et al, 2011), suggesting that ESR1 might be transcriptionally repressed during acquired resistance to tamoxifen. Here, ESR1 is linked to breast carcinoma.